Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -1.3818.82-27.0420.6731.28

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is -1.38 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67
Mar202131.28

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67
-33.92
Mar2021 31.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹30,665.2 Cr -3.6% -4.1% 15.4% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹406,147.0 Cr 0.2% 2.3% -9.3% Stock Analytics
DIVIS LABORATORIES ₹176,708.0 Cr -1.3% 9.1% 16.7% Stock Analytics
CIPLA ₹121,525.0 Cr 0.2% -0.6% -3.8% Stock Analytics
TORRENT PHARMACEUTICALS ₹121,147.0 Cr 0.6% 1% 10.8% Stock Analytics
DR REDDYS LABORATORIES ₹100,596.0 Cr 0.6% -3.5% -4.3% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-3.6%

-4.1%

15.4%

SENSEX

-1.4%

1.7%

4.8%


You may also like the below Video Courses